Cargando…

The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium

AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ørstavik, Øivind, Manfra, Ornella, Andressen, Kjetil Wessel, Andersen, Geir Øystein, Skomedal, Tor, Osnes, Jan-Bjørn, Levy, Finn Olav, Krobert, Kurt Allen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349697/
https://www.ncbi.nlm.nih.gov/pubmed/25738589
http://dx.doi.org/10.1371/journal.pone.0115547
_version_ 1782360065891631104
author Ørstavik, Øivind
Manfra, Ornella
Andressen, Kjetil Wessel
Andersen, Geir Øystein
Skomedal, Tor
Osnes, Jan-Bjørn
Levy, Finn Olav
Krobert, Kurt Allen
author_facet Ørstavik, Øivind
Manfra, Ornella
Andressen, Kjetil Wessel
Andersen, Geir Øystein
Skomedal, Tor
Osnes, Jan-Bjørn
Levy, Finn Olav
Krobert, Kurt Allen
author_sort Ørstavik, Øivind
collection PubMed
description AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term clinical effects of levosimendan, also results from PDE3 inhibition, we compared the effects of OR-1896, a representative Ca(2+) sensitizer EMD57033 (EMD), levosimendan and other PDE inhibitors. METHODS: Contractile force was measured in rat ventricular strips. PDE assay was conducted on rat ventricular homogenate. cAMP was measured using RII_epac FRET-based sensors. RESULTS: OR-1896 evoked a maximum PIR of 33±10% above basal at 1 μM. This response was amplified in the presence of the PDE4 inhibitor rolipram (89±14%) and absent in the presence of the PDE3 inhibitors cilostamide (0.5±5.3%) or milrinone (3.2±4.4%). The PIR was accompanied by a lusitropic response, and both were reversed by muscarinic receptor stimulation with carbachol and absent in the presence of β-AR blockade with timolol. OR-1896 inhibited PDE activity and increased cAMP levels at concentrations giving PIRs. OR-1896 did not sensitize the concentration-response relationship to extracellular Ca(2+). Levosimendan, OR-1896 and EMD all increased the sensitivity to β-AR stimulation. The combination of either EMD and levosimendan or EMD and OR-1896 further sensitized the response, indicating at least two different mechanisms responsible for the sensitization. Only EMD sensitized the α(1)-AR response. CONCLUSION: The observed PIR to OR-1896 in rat ventricular strips is mediated through PDE3 inhibition, enhancing cAMP-mediated effects. These results further reinforce our previous finding that Ca(2+) sensitization does not play a significant role in the inotropic (and lusitropic) effect of levosimendan, nor of its main metabolite OR-1896.
format Online
Article
Text
id pubmed-4349697
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43496972015-03-17 The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium Ørstavik, Øivind Manfra, Ornella Andressen, Kjetil Wessel Andersen, Geir Øystein Skomedal, Tor Osnes, Jan-Bjørn Levy, Finn Olav Krobert, Kurt Allen PLoS One Research Article AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term clinical effects of levosimendan, also results from PDE3 inhibition, we compared the effects of OR-1896, a representative Ca(2+) sensitizer EMD57033 (EMD), levosimendan and other PDE inhibitors. METHODS: Contractile force was measured in rat ventricular strips. PDE assay was conducted on rat ventricular homogenate. cAMP was measured using RII_epac FRET-based sensors. RESULTS: OR-1896 evoked a maximum PIR of 33±10% above basal at 1 μM. This response was amplified in the presence of the PDE4 inhibitor rolipram (89±14%) and absent in the presence of the PDE3 inhibitors cilostamide (0.5±5.3%) or milrinone (3.2±4.4%). The PIR was accompanied by a lusitropic response, and both were reversed by muscarinic receptor stimulation with carbachol and absent in the presence of β-AR blockade with timolol. OR-1896 inhibited PDE activity and increased cAMP levels at concentrations giving PIRs. OR-1896 did not sensitize the concentration-response relationship to extracellular Ca(2+). Levosimendan, OR-1896 and EMD all increased the sensitivity to β-AR stimulation. The combination of either EMD and levosimendan or EMD and OR-1896 further sensitized the response, indicating at least two different mechanisms responsible for the sensitization. Only EMD sensitized the α(1)-AR response. CONCLUSION: The observed PIR to OR-1896 in rat ventricular strips is mediated through PDE3 inhibition, enhancing cAMP-mediated effects. These results further reinforce our previous finding that Ca(2+) sensitization does not play a significant role in the inotropic (and lusitropic) effect of levosimendan, nor of its main metabolite OR-1896. Public Library of Science 2015-03-04 /pmc/articles/PMC4349697/ /pubmed/25738589 http://dx.doi.org/10.1371/journal.pone.0115547 Text en © 2015 Ørstavik et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ørstavik, Øivind
Manfra, Ornella
Andressen, Kjetil Wessel
Andersen, Geir Øystein
Skomedal, Tor
Osnes, Jan-Bjørn
Levy, Finn Olav
Krobert, Kurt Allen
The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title_full The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title_fullStr The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title_full_unstemmed The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title_short The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
title_sort inotropic effect of the active metabolite of levosimendan, or-1896, is mediated through inhibition of pde3 in rat ventricular myocardium
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349697/
https://www.ncbi.nlm.nih.gov/pubmed/25738589
http://dx.doi.org/10.1371/journal.pone.0115547
work_keys_str_mv AT ørstavikøivind theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT manfraornella theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT andressenkjetilwessel theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT andersengeirøystein theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT skomedaltor theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT osnesjanbjørn theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT levyfinnolav theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT krobertkurtallen theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT ørstavikøivind inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT manfraornella inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT andressenkjetilwessel inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT andersengeirøystein inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT skomedaltor inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT osnesjanbjørn inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT levyfinnolav inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium
AT krobertkurtallen inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium